Astrazeneca plc

NASDAQ: AZN
$66.27
-$5.16 (-7.2%)
Closing Price on November 5, 2024

AZN Stock Chart and Intraday Price

AZN Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE, GB
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 200,284.54M USD
Shares Outstanding 3,100,380,000
AstraZeneca is a global biopharmaceutical giant, dedicated to the discovery, development, and commercialization of prescription medicines. Its portfolio spans a wide range of areas including cardiovascular, renal, metabolism, oncology, and treatments for rare diseases and COVID-19. The company is known for leading products like Tagrisso, Imfinzi, and Lynparza, among others. AstraZeneca not only serves healthcare professionals and patients worldwide but also engages in significant collaborations, such as with Neurimmune AG, to push the boundaries of medicine. Headquartered in Cambridge, UK, AstraZeneca continues to be at the forefront of addressing global health challenges.

AZN Articles

These five blue chip dividend stocks would be ideal for investors who had to hold them forever, as they provide reliable streams of passive income.
George Soros is among the most renowned and controversial hedge fund managers on the planet. Well known for his political affiliations, which are now opposite to a number of politically-charged CEOs...
Billionaire investor George Soros became nearly a household name in the early 1990’s by shorting the British pound and making $1 billion on the deal. His currency speculation earned him the...
Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what the company's prospects are for the next decade of growth.
24/7 Insights With the S&P 500 up 15% year-to-date, a correction could be coming in the third quarter. Stocks that pay dividends will be in big demand when interest rates start to fall over the...
24/7 Insights Quality dividend stocks outperform non-dividend stocks for shareholders. Dividend stocks can deliver dependable passive income streams. Access 2 legendary, high-yield dividend stocks...
With the pandemic largely in the rear-view mirror, COVID-19 vaccine winner Novavax has seen shares fall. Yet, analysts have high hopes for the stock.
Here is an assessment of how safe the dividend at AbbVie appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Analysts have been cutting ratings and price targets recently, but here are four stocks that defying the downward pressure.
This year’s Artificial Intelligence rally led by the so-called “Magnificent 7” has been fantastic if you owned those stocks. The reality is the great bulk of the S&P 500 is treading water...
The federal CHIPS Act signed into law by President Joe Biden in August 2022 is offering $52 billion in federal subsidies to boost America’s semiconductor industry. The goal is to reduce U.S....
Tuesday's top analyst upgrades and downgrades included AstraZeneca, Ballard Power Systems, Bloom Energy, BHP, Cleveland-Cliffs, CrowdStrike, Dow, Nike, Plains All-American Pipeline, Sealed Air and...
Friday's top analyst upgrades and downgrades included Ally Financial, American Express, AppLovin, AstraZeneca, Coinbase Global, Cognizant Technology Solutions, Comcast, CME, CrowdStrike, Delta Air...
Before U.S. markets open on Thursday, these three companies will be among those reporting quarterly earnings.
Wednesday's additional top analyst upgrades and downgrades were on AstraZeneca, Bilibili, Electronic Arts, GoodRx, NetEase, Netflix, Pinterest, U.S. Foods and more.